How Can Patient Data be Used to Lower Drug Costs?



 
Ogurchak: The availability of patient data and some of the specificity we can capture as a specialty pharmacy—particularly as it relates to adherence measures and outcomes measures—really helps us view that patient’s journey overall and help us act proactively.
 
The more that we know about adherence, the more that we know about how well patients are responding or not, really gives us the ability to make sure patients maintain on therapy and not incur additional spend that might occur with nonadherence.

Most Popular

Related Articles

Ron Lanton III, Esq., executive director and senior counsel for Frier Levitt Government Affairs, discusses the need for increased pharmacy benefit manager regulation on a federal level.
Researchers have determined that many potentially adverse effects are not present on fact-based health care reviews.
The economics of one and done gene therapies dictate a revenue model that requires outcomes-based risk.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$